相关实验视频
Updated: Jan 22, 2026

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
13.3K
对心力衰竭的基于注册表的研究的观点:当前状态和未来方向
Christian Basile1,2, Felix Lindberg1, Gianluigi Savarese3
1Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden.
Korean circulation journal
|January 21, 2026
概括
心力衰竭 (HF) 登记处跟踪数百万患者,提供超越临床试验的真实洞察力. 这些注册表对于改善患者护理和通过创新方法推进HF研究至关重要.
科学领域:
- 心脏病学 心脏病学
- 临床研究 临床研究
- 医疗信息学 医疗信息学
背景情况:
- 心力衰竭 (HF) 登记处弥合了临床试验和实践之间的差距.
- 数以百万计的患者已经在全球注册表中被纳入各种高频谱.
- 早期的倡议,如ADHERE和欧洲心脏衰竭调查,为更大的计划铺平了道路.
研究的目的:
- 提供HF注册表演变的全球概述.
- 分析HF注册的科学产量和影响.
- 讨论HF注册表研究的未来潜力和进展.
主要方法:
- 全球历史和当前心力衰竭登记处的审查.
- 基于登记册的研究对HF流行病学,表型和治疗的分析.
- 基于注册表的随机对照试验的探索和方法学的进步.
主要成果:
- 登记册为人们提供了有关HF流行病学,风险因素和现实世界治疗的见解.
- 它们解决了随机试验中不可行的问题,比如治疗中断.
- 基于注册表的试验以更低的成本提供实用干预测试.
结论:
- 对于一个学习的医疗保健系统来说,HF注册表是必不可少的.
- 方法学的进步提高了注册表的有效性和相关性.
- 未来的潜力在于利用电子记录和因果推理技术.
相关概念视频
Heart Failure II: Pathophysiology
783
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
783
Pathophysiology of Heart Failure
3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction
723
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
723
Heart Failure VI: Adjunct Therapies
277
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
277
Heart Failure Drugs: Diuretics
824
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
824
Heart Failure V: Medical Management
227
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
227

